|RAS010-C01||Pre-coated Anti-SARS-CoV-2 Nucleocapsid Antibody Microplate||1 plate|
|RAS010-C02||SARS-CoV-2 Nucleocapsid Protein||10 ug|
|RAS010-C03||Biotin-Anti-SARS-CoV-2 Nucleocapsid Antibody||100 μL|
|RAS010-C05||10xWashing Buffer||50 mL|
|RAS010-C06||Dilution Buffer||50 mL|
|RAS010-C07||Substrate Solution||12 mL|
|RAS010-C08||Stop Solution||7 mL|
Upon receipt, please store the lyophilized products at -20℃. After reconstitution, the stock solution should be kept at -70℃.
It is recommended not to freeze thaw more than 3 times.
Your experiment will include 6 simple steps:
a) Coat the plate with Anti-SARS-CoV-2 Nucleocapsid Antibody.
b) After washing and blocking, add your sample to the plate, take the SARS-CoV-2 Nucleocapsid protein as Control sample. The samples and Control sample are diluted by Lysis Buffer.
c) Add a diluted Secondary antibody biotin-anti-SARS-CoV-2 Nucleocapsid Antibody to the plate. The Secondary antody is diluted by Dilution Buffer.
d) Add a diluted Streptavidin-HRP to the plate.
e) Wash the plate and add TMB or other colorimetric HRP substrate.
f) Stop the substrate reaction by add diluted acid. Absorbance (OD) is calculate as the absorbance at 450 nm minus the absorbance at 650 nm to remove background prior to statistical analysis. The OD Value reflects the amount of antibody bound.
Detection of Monoclonal SARS-CoV-2 Nucleocapsid Protein titer by sandwich-ELISA Assay.
Immobilized Anti-SARS-CoV-2 Nucleocapsid Protein Antibody at 4 μg/mL (100 μL/well) can bind SARS-CoV-2 Nucleocapsid Protein and Biotin-Anti-SARS-CoV-2 Nucleocapsid Antibody. Detection was performed using Streptavidin-HRP with sensitivity of 12.5 pg/mL (QC tested).
Emerging VoCs, Lambda, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ELISA kits for neutralizing antibody titer assay, binding antibody titer assay, antibody isotype assay, antigen titer assay and inhibitor screening, etc., which can accelerate the research and development of anti-SARS-CoV-2 drugs and vaccines.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
This web search service is supported by Google Inc.